Navigation Links
Normal Cells May Predict Cancer Virulence

Finding suggests that treatment that only aims at malignant cells might fall short

THURSDAY, Aug. 28 (HealthDay News) -- Characteristics of normal cells which are present long before any tumor appears may determine how virulent a particular cancer is going to be, new research suggests.

Such cells may travel early on to distant sites in the body, residing innocently there until certain cancer genes are turned on.

"It's definitely conceptually very profound," said Dr. Katrina Podsypanina, a senior research scientist at Memorial-Sloan Kettering Cancer Center in New York City. "Our data seems to point toward the inherent decision that is made when the tumor is formed whether it is highly malignant or not. Moreover, since the characteristic might be dependent on the normal cell status, one might imagine that they might be different between individuals."

The study's senior author is Harold Varmus, who won the 1989 Nobel Prize for his work in cancer genetics and later went on to become director of the National Institutes of Health.

The finding implies that treatments that only target malignant cells may not be effective.

So far, however, the findings have only been shown in mice, and the research involved certain processes that were imposed which wouldn't normally occur in the human body.

"This does suggest that cells can sit for a long time, then be activated," said Dr. Claudine Isaacs, director of the clinical breast cancer program at Georgetown's Lombardi Comprehensive Cancer Center in Washington, D.C. "But these cells were injected into the circulation. Normal breast cells are not supposed to be in the circulation."

Also, the normal cells didn't form tumors until activated.

Conventional medical wisdom holds that the spread of a cancer occurs relatively late in the life of a cancer, happening only after cells from the primary tumor have undergone enough mutations to switch on different cancer genes.

Podsypanina and her colleagues performed a series of experiments in mice.

First, they injected normal mammary cells that contained cancer-inducing oncogenes, which could be switched on and off. These cells migrated through the bloodstream to the lungs, residing there for four months. They did not begin to grow aggressively until the oncogenes had been turned on, but they did so without first going through the stage of being a primary tumor.

Next, they injected normal cells without manipulating any oncogenes.

"Cells that did not have any oncogenes in them and do not transform spontaneously as per all published studies, we could see little colonies of these cells when we inspected the lungs," Podsypanina said. "At no point, never, did we see a solid vision that would resemble metastatic colonies, [but] it appears that every time we looked at the animal, the colonies appeared to be larger."

When these normal ectopic cells were injected back into a new generation of mice, they developed into normal mammary glands.

"It's a beginning," Podsypanina said. "It's an important step to show whether or not the first step of the metastatic cascade is something a normal cell can accomplish."

More information

Visit the American Cancer Society for more on oncogenes.

SOURCES: Katrina Podsypanina, M.D., Ph.D., senior research scientist, department of cancer biology and genetics, Memorial Sloan-Kettering Cancer Center, New York City; Claudine Isaacs, M.D., director, clinical breast cancer program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C.; Aug. 28, 2008, Science

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Clinical depression linked to abnormal emotional brain circuits
2. Brain imaging reveals breakdown of normal emotional processing
3. Normal role for schizophrenia risk gene identified
4. Novadaq Resumes Normal Business Operations by Securing ICG for SPY
5. How Candida albicans transforms from its normally benign form into life-threatening form
6. Grant Supports Study of Abnormal Ring-Shaped Chromosomes
7. How shyness and other normal human traits became sickness
8. Key Cleaning Solutions Products Utilized to Combat Community Acquired - MRSA (CA-MRSA) Are Succeeding In Killing Superbugs Where Normal Cleaning Practices and Products Are Not
9. Normal tissue not spared in new forms of breast cancer radiotherapy
10. Abnormal immune cells may cause unprovoked anaphylaxis
11. Abnormal glutamine repeats interfere with key transcription factor, leading to neurodegeneration
Post Your Comments:
Related Image:
Normal Cells May Predict Cancer Virulence
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... , , , WHEN: , , ... , , , LOCATION: , , , Online, with free registration ... PANELISTS:  , , , Frost & Sullivan,s Global Vice President of ... Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... witnessing an exceptional era. Several new demand spaces, such as innovative ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: